Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
Dig Dis
    July 2021
  1. OSWALD L, Nakanishi H, Kurosaki M, Kirino S, et al
    Plasma renin activity predicts prognosis and liver disease-related events in liver cirrhosis patients with ascites treated by tolvaptan.
    Dig Dis. 2021 Jul 30. pii: 000518099. doi: 10.1159/000518099.
    >> Share

    June 2021
  2. OCAL O, Rossler D, Ricke J, Seidensticker M, et al
    Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma.
    Dig Dis. 2021 Jun 29. pii: 000518101. doi: 10.1159/000518101.
    >> Share

  3. KUBOTA K, Uojima H, Shao X, Iwasaki S, et al
    Additional L-carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.
    Dig Dis. 2021 Jun 28. pii: 000518067. doi: 10.1159/000518067.
    >> Share

  4. OP DEN WINKEL M, Nagel D, de la Torre Alaez MA, Hempe S, et al
    A simple prognostic scoring system for hepatocellular carcinoma treated with selective internal radiation therapy.
    Dig Dis. 2021 Jun 10. pii: 000517458. doi: 10.1159/000517458.
    >> Share

    May 2021
  5. KRSTIC MN, Mijac D, Tomasevic RS, Lukic S, et al
    Abnormal liver blood tests: Hepatologist approach.
    Dig Dis. 2021 May 10. pii: 000517110. doi: 10.1159/000517110.
    >> Share

    April 2021
  6. MEYER JJ, Dreyhaupt J, Schwerdel D, Ettrich TJ, et al
    Blood-based targeted metabolomics discriminate patients with alcoholic liver cirrhosis from those with non-cirrhotic liver damage: an explorative study.
    Dig Dis. 2021 Apr 16. pii: 000516488. doi: 10.1159/000516488.
    >> Share

  7. MANZHALII E, Falalyeyeva TM, Moyseyenko VO, Weiskirchen R, et al
    Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor?
    Dig Dis. 2021 Apr 9. pii: 000516412. doi: 10.1159/000516412.
    >> Share

    January 2021
  8. KUSNIK A, Hunter N, Rasbach E, Miethke T, et al
    Co-Medication and nutrition in HCC: Potentially preventative strategies in Hepatocellular carcinoma (HCC).
    Dig Dis. 2021 Jan 11. pii: 000514277. doi: 10.1159/000514277.
    >> Share

  9. ANASTASIOU OE, Korth J, Herbstreit F, Witzke O, et al
    Mild versus Severe Liver Injury in SARS-CoV-2 Infection.
    Dig Dis. 2021;39:52-57.
    >> Share

  10. WEBER S, Benesic A, Buchholtz ML, Rotter I, et al
    Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury.
    Dig Dis. 2021;39:275-282.
    >> Share

  11. XU Y, Hu X, Li J, Dong R, et al
    An Improved Scoring System Based on Platelet-Albumin-Bilirubin in Predicting Posthepatectomy Liver Failure Outcomes.
    Dig Dis. 2021;39:258-265.
    >> Share

  12. WADA N, Uojima H, Satoh T, Okina S, et al
    Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Dig Dis. 2021;39:234-242.
    >> Share

    November 2020
  13. IDILMAN R, Aydogan M, Oruncu MB, Kartal A, et al
    Dig Dis. 2020 Nov 3. pii: 000512746. doi: 10.1159/000512746.
    >> Share

  14. SCHINDLER P, Masthoff M, Harders F, Schmidt H, et al
    Dig Dis. 2020 Nov 3. pii: 000512744. doi: 10.1159/000512744.
    >> Share

    September 2020
  15. BARABAS L, Hritz I, Istvan G, Tulassay Z, et al
    The behavior of MMP-2, MMP-7, MMP-9 and their inhibitors TIMP-1, TIMP-2 in adenoma-colorectal cancer sequence.
    Dig Dis. 2020 Sep 22. pii: 000511765. doi: 10.1159/000511765.
    >> Share

    August 2020
  16. MOON AM, Watkins SE, Lok AS, Firpi-Morell RJ, et al
    Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
    Dig Dis. 2020 Aug 24. pii: 000511074. doi: 10.1159/000511074.
    >> Share

  17. RAMRAKHIANI NS, Le M, Yeo YH, Le A, et al
    Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis.
    Dig Dis. 2020 Aug 19. pii: 000510981. doi: 10.1159/000510981.
    >> Share

    May 2020
  18. KIMURA N, Tsuchiya A, Oda C, Kimura A, et al
    Visceral adipose tissue index and hepatocellular carcinoma are independent predictors of outcome in patients with cirrhosis having endoscopic treatment for esophageal varices.
    Dig Dis. 2020 May 25. pii: 000508867. doi: 10.1159/000508867.
    >> Share

    March 2020
  19. MILOVANOVIC T, Popovic D, Stojkovic Lalosevic M, Dumic I, et al
    Quality Of Life in Patients With Primary Biliary Cholangitis: A Single Center Experience in Serbia.
    Dig Dis. 2020 Mar 6. pii: 000506980. doi: 10.1159/000506980.
    >> Share

  20. KANG MK, Kim KO, Kim MC, Park JG, et al
    Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Dig Dis. 2020 Mar 5. pii: 000506938. doi: 10.1159/000506938.
    >> Share

    February 2020
  21. AINORA ME, Iezzi R, Ponziani FR, Garcovich M, et al
    Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment.
    Dig Dis. 2020 Feb 13. pii: 000506455. doi: 10.1159/000506455.
    >> Share

    January 2020
  22. SINGH SK, Sen Sarma M, Yachha SK, Srivastava A, et al
    Late-Onset Hepatic Failure in Children: Risk Factors that Determine the Outcome.
    Dig Dis. 2020 Jan 15:1-6. doi: 10.1159/000505124.
    >> Share

  23. DITE P, Blaho M, Bojkova M, Jabandziev P, et al
    Nonalcoholic Fatty Pancreas Disease: Clinical Consequences.
    Dig Dis. 2020;38:143-149.
    >> Share

  24. BLACKETT JW, Verna EC, Lebwohl B
    Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.
    Dig Dis. 2020;38:222-230.
    >> Share

    December 2019
  25. ARORA MS, Kaushik R, Ahmad S, Kaushik RM, et al
    Profile of Acute Kidney Injury in Patients with Decompensated Cirrhosis at a Tertiary-Care Center in Uttarakhand, India.
    Dig Dis. 2019 Dec 12:1-9. doi: 10.1159/000504836.
    >> Share

  26. OGURA T, Yamada T, Yamada M, Ueno S, et al
    Triple Covered Metal Stent Deployment Using Side-by-Side Technique for Hemobilia due to Hepatocellular Carcinoma (with Video).
    Dig Dis. 2019 Dec 12:1-4. doi: 10.1159/000504384.
    >> Share

    October 2019
  27. REICHERT MC, Schulz A, Massmann A, Buecker A, et al
    Predictive Power of Liver Maximum Function Capacity Test in Transjugular Intrahepatic Portosystemic Shunt Patients: A Pilot Study.
    Dig Dis. 2019 Oct 16:1-8. doi: 10.1159/000503098.
    >> Share

  28. MONTES-CORTES DH, Olivares-Corichi IM, Rosas-Barrientos JV, Manuel-Apolinar L, et al
    Characterization of Oxidative Stress and Ammonia According to the Different Grades of Hepatic Encephalopathy.
    Dig Dis. 2019 Oct 2:1-11. doi: 10.1159/000503097.
    >> Share

    June 2019
  29. UOJIMA H, Hidaka H, Tanaka Y, Wada N, et al
    Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
    Dig Dis. 2019 Jun 19:1-8. doi: 10.1159/000501267.
    >> Share

  30. LASHEN SA, Shamseya MM, Madkour MA
    Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
    Dig Dis. 2019 Jun 19:1-10. doi: 10.1159/000501072.
    >> Share

  31. FACCIORUSSO A, Buccino VR, Del Prete V, Antonino M, et al
    Cirrhosis Is a Predictor of Adverse Events in Endoscopic Ultrasound Fine-Needle Aspiration: A Propensity-Score Analysis.
    Dig Dis. 2019 Jun 18:1-8. doi: 10.1159/000501268.
    >> Share

  32. MANZHALII E, Virchenko O, Falalyeyeva T, Moiseienko V, et al
    Hepatic Encephalopathy Aggravated by Systemic Inflammation.
    Dig Dis. 2019 Jun 6:1-9. doi: 10.1159/000500717.
    >> Share

    January 2019
  33. AZUMA S, Asahina Y, Kakinuma S, Azuma K, et al
    Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000493580.
    >> Share

  34. KIDA Y
    Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000494438.
    >> Share

  35. SHIRIN D, Peleg N, Sneh-Arbib O, Cohen-Naftaly M, et al
    The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.
    Dig Dis. 2019;37:69-76.
    >> Share

  36. CAMPOS AMICO E, de Souza IK, Grigorio Trigueiro JR, Cunha Miranda F, et al
    Should Focal Nodular Hyperplasia Still be Operated Upon? Analysis of a Case Series.
    Dig Dis. 2019;37:309-314.
    >> Share

  37. SERRANO CA, Ling SC, Verdaguer S, Leon M, et al
    Portal Angiogenesis in Chronic Liver Disease Patients Correlates with Portal Pressure and Collateral Formation.
    Dig Dis. 2019;37:498-508.
    >> Share

    November 2018
  38. SCHULZ C, Schutte K, Vilchez-Vargas R, Vasapolli R, et al
    Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Dig Dis. 2018 Nov 14:1-9. doi: 10.1159/000494216.
    >> Share

    September 2018
  39. GOTTLIEB A, Kottmann M, Manka P, Bedreli S, et al
    How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.
    Dig Dis. 2018 Sep 18:1-8. doi: 10.1159/000492869.
    >> Share

    July 2018
  40. BUTTERWORTH RF, Canbay A
    Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2018 Jul 17:1-6. doi: 10.1159/000491429.
    >> Share

  41. LONGO L, de Freitas LBR, Santos D, Grivicich I, et al
    Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
    Dig Dis. 2018 Jul 13:1-8. doi: 10.1159/000490378.
    >> Share

  42. FURUTA M, Moriguchi M, Okuda K, Kataoka S, et al
    Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma.
    Dig Dis. 2018 Jul 3:1-10. doi: 10.1159/000489488.
    >> Share

    May 2018
  43. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    >> Share

    March 2018
  44. ZOU H, Yang X, Li QL, Zhou QX, et al
    A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients.
    Dig Dis. 2018 Mar 1. pii: 000486590. doi: 10.1159/000486590.
    >> Share

    January 2018
  45. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    >> Share

  46. BUECHTER M, Manka P, Gerken G, Canbay A, et al
    Transjugular Intrahepatic Portosystemic Shunt in Patients with Portal Hypertension: Patency Depends on Coverage and Interventionalist's Experience.
    Dig Dis. 2018 Jan 9. pii: 000486030. doi: 10.1159/000486030.
    >> Share

  47. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    >> Share

  48. TAKATORI Y, Kato M, Sunata Y, Hirai Y, et al
    The Role of History of Gastro-Duodenal Ulcer in Patients with Upper Gastrointestinal Bleeding.
    Dig Dis. 2018;36:177-181.
    >> Share

  49. PAN X, Han Y, Zou T, Zhu G, et al
    Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Dig Dis. 2018;36:427-436.
    >> Share

  50. NISHIOKA Y, Shindoh J, Inagaki Y, Gonoi W, et al
    Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
    Dig Dis. 2018;36:437-445.
    >> Share

    November 2017
  51. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    >> Share

    October 2017
  52. DYWICKI J, Noyan F, Misslitz AC, Hapke M, et al
    Hepatic T Cell Tolerance Induction in An Inflammatory Environment.
    Dig Dis. 2017 Oct 12. doi: 10.1159/000481341.
    >> Share

    July 2017
  53. XIAO W, Zheng J, Zhou B, Pan L, et al
    Replication Protein A 3 Is Associated with Hepatocellular Carcinoma Tumorigenesis and Poor Patient Survival.
    Dig Dis. 2017 Jul 7. doi: 10.1159/000478977.
    >> Share

  54. LABENZ C, Prenosil V, Koch S, Huber Y, et al
    Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Dig Dis. 2017 Jul 4. doi: 10.1159/000477578.
    >> Share

    January 2017
  55. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    >> Share

  56. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    >> Share

  57. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    >> Share

  58. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    >> Share

  59. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    >> Share

  60. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    >> Share

  61. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    >> Share

  62. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    >> Share

  63. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    >> Share

  64. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    >> Share

  65. NEVENS F
    Novel Approaches to Reducing the Risk of Variceal Hemorrhage.
    Dig Dis. 2017;35:397-401.
    >> Share

  66. ROWE IA
    Lessons from Epidemiology: The Burden of Liver Disease.
    Dig Dis. 2017;35:304-309.
    >> Share

  67. TOWNSEND SA, Newsome PN
    The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016.
    Dig Dis. 2017;35:371-376.
    >> Share

  68. CHUNG BK, Karlsen TH
    Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease.
    Dig Dis. 2017;35:323-333.
    >> Share

  69. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    >> Share

    Stemness in Liver Cancer.
    Dig Dis. 2017;35:387-389.
    >> Share

  71. BAWDEN SJ, Scott RA, Aithal GP
    Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.
    Dig Dis. 2017;35:314-322.
    >> Share

  72. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    >> Share

  73. HIRAOKA A, Kumada T, Kudo M, Hirooka M, et al
    Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Dig Dis. 2017;35:602-610.
    >> Share

  74. NISHIDA N, Kudo M
    Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Dig Dis. 2017;35:618-622.
    >> Share

  75. UESHIMA K, Nishida N, Kudo M
    Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Dig Dis. 2017;35:611-617.
    >> Share

  76. ISHIKAWA T, Imai M, Owaki T, Sato H, et al
    Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study.
    Dig Dis. 2017;35:598-601.
    >> Share

  77. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Dig Dis. 2017;35:589-597.
    >> Share

  78. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Dig Dis. 2017;35:583-588.
    >> Share

  79. IWAMOTO T, Imai Y, Igura T, Kogita S, et al
    Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellula
    Dig Dis. 2017;35:574-582.
    >> Share

  80. IDA H, Hagiwara S, Kono M, Minami T, et al
    Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Dig Dis. 2017;35:565-573.
    >> Share

  81. UMEHARA Y, Hagiwara S, Nishida N, Sakurai T, et al
    Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.
    Dig Dis. 2017;35:548-555.
    >> Share

  82. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    >> Share

  83. KITAHATA S, Hiraoka A, Kudo M, Murakami T, et al
    Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma.
    Dig Dis. 2017;35:498-505.
    >> Share

  84. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016